BNP Paribas Financial Markets Increases Position in Quanterix Co. (NASDAQ:QTRX)

BNP Paribas Financial Markets boosted its position in shares of Quanterix Co. (NASDAQ:QTRX - Free Report) by 756.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,896 shares of the company's stock after purchasing an additional 57,319 shares during the period. BNP Paribas Financial Markets owned approximately 0.17% of Quanterix worth $690,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of QTRX. Ameriprise Financial Inc. increased its holdings in shares of Quanterix by 111.3% during the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company's stock worth $34,079,000 after buying an additional 1,688,680 shares during the last quarter. William Blair Investment Management LLC purchased a new position in Quanterix in the fourth quarter worth approximately $11,290,000. Pier Capital LLC increased its stake in Quanterix by 32.8% during the fourth quarter. Pier Capital LLC now owns 679,680 shares of the company's stock worth $7,225,000 after acquiring an additional 167,882 shares during the last quarter. Valmark Advisers Inc. increased its stake in Quanterix by 88.3% during the fourth quarter. Valmark Advisers Inc. now owns 210,878 shares of the company's stock worth $2,242,000 after acquiring an additional 98,883 shares during the last quarter. Finally, Easterly Investment Partners LLC raised its position in Quanterix by 9.0% in the fourth quarter. Easterly Investment Partners LLC now owns 954,995 shares of the company's stock valued at $10,152,000 after purchasing an additional 78,862 shares during the period. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Trading Up 3.6%

QTRX traded up $0.18 during trading hours on Tuesday, hitting $5.03. 258,076 shares of the company's stock were exchanged, compared to its average volume of 572,348. The firm has a market cap of $195.12 million, a P/E ratio of -4.75 and a beta of 1.12. Quanterix Co. has a 12-month low of $4.05 and a 12-month high of $19.18. The firm has a 50 day moving average of $5.60 and a 200 day moving average of $8.36.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.16. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. The business had revenue of $30.33 million during the quarter, compared to the consensus estimate of $28.27 million. As a group, research analysts expect that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Leerink Partners reiterated a "market perform" rating and set a $8.00 price target (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a research report on Tuesday, March 25th. Wall Street Zen downgraded shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group dropped their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $15.60.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.